X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11419) 11419
Publication (1256) 1256
Book Review (150) 150
Book Chapter (39) 39
Book / eBook (23) 23
Conference Proceeding (23) 23
Web Resource (15) 15
Dissertation (13) 13
Magazine Article (8) 8
Data Set (4) 4
Streaming Video (3) 3
Paper (2) 2
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9095) 9095
index medicus (6633) 6633
animals (3893) 3893
oncology (3882) 3882
protein-tyrosine kinases - antagonists & inhibitors (3593) 3593
female (3108) 3108
tyrosine (3058) 3058
male (2900) 2900
antineoplastic agents - therapeutic use (2698) 2698
cancer (2692) 2692
protein-tyrosine kinase (2663) 2663
protein kinase inhibitors - therapeutic use (2479) 2479
kinases (2372) 2372
mice (2035) 2035
mutation (1880) 1880
middle aged (1799) 1799
signal transduction (1780) 1780
research (1672) 1672
phosphorylation (1586) 1586
adult (1531) 1531
pyrimidines - therapeutic use (1509) 1509
proteins (1461) 1461
aged (1438) 1438
cell line, tumor (1403) 1403
research article (1373) 1373
multidisciplinary sciences (1359) 1359
medicine (1358) 1358
tumors (1358) 1358
imatinib mesylate (1356) 1356
protein-tyrosine kinases - metabolism (1301) 1301
lung neoplasms - drug therapy (1227) 1227
expression (1223) 1223
care and treatment (1217) 1217
cell biology (1160) 1160
apoptosis (1149) 1149
protein kinase inhibitors - pharmacology (1138) 1138
treatment outcome (1137) 1137
chemotherapy (1126) 1126
science (1123) 1123
genetic aspects (1121) 1121
antineoplastic agents - pharmacology (1110) 1110
hematology (1106) 1106
benzamides (1084) 1084
gene expression (1080) 1080
receptor protein-tyrosine kinases - genetics (1075) 1075
health aspects (1055) 1055
pharmacology & pharmacy (1054) 1054
piperazines - therapeutic use (1007) 1007
activation (989) 989
receptor protein-tyrosine kinases - antagonists & inhibitors (988) 988
article (987) 987
lung cancer (981) 981
receptor protein-tyrosine kinases - metabolism (969) 969
carcinoma, non-small-cell lung - drug therapy (960) 960
metastasis (945) 945
analysis (918) 918
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (906) 906
signal transduction - drug effects (887) 887
biochemistry & molecular biology (885) 885
lung neoplasms - genetics (840) 840
protein-tyrosine kinases - genetics (826) 826
biology (817) 817
patients (815) 815
physiological aspects (791) 791
leukemia (783) 783
prognosis (778) 778
tyrosine kinase inhibitor (771) 771
imatinib (759) 759
therapy (755) 755
epidermal growth factor (746) 746
inhibitors (722) 722
enzyme inhibitors - therapeutic use (711) 711
cancer therapies (707) 707
survival (705) 705
tyrosine kinase (698) 698
hemic and lymphatic diseases (680) 680
neoplasms - drug therapy (669) 669
protein-tyrosine kinase receptors (669) 669
inhibition (640) 640
angiogenesis (639) 639
rodents (638) 638
lung neoplasms - pathology (629) 629
aged, 80 and over (627) 627
drug therapy (626) 626
chronic myelogenous leukemia (625) 625
cell proliferation (620) 620
drug resistance, neoplasm (620) 620
tyrosine kinase inhibitors (617) 617
antineoplastic combined chemotherapy protocols - therapeutic use (612) 612
carcinoma, non-small-cell lung - genetics (603) 603
cells (600) 600
breast cancer (596) 596
epidermal growth factor receptors (593) 593
growth-factor receptor (585) 585
pyrimidines - pharmacology (573) 573
immunology (569) 569
chronic myeloid-leukemia (567) 567
pyridines - therapeutic use (567) 567
rats (567) 567
pyrazoles - therapeutic use (565) 565
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10906) 10906
Japanese (134) 134
French (119) 119
German (111) 111
Chinese (86) 86
Hungarian (31) 31
Spanish (20) 20
Russian (16) 16
Polish (15) 15
Czech (13) 13
Dutch (8) 8
Italian (8) 8
Norwegian (4) 4
Swedish (4) 4
Danish (3) 3
Finnish (3) 3
Bulgarian (2) 2
Croatian (2) 2
Portuguese (2) 2
Romanian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Nature Chemical Biology, ISSN 1552-4450, 01/2011, Volume 7, Issue 1, pp. 41 - 50
Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and molecular mechanisms by which Btk mediates inflammation... 
RHEUMATOID-ARTHRITIS | COLLAGEN-INDUCED ARTHRITIS | BRUTONS TYROSINE KINASE | ACTIVATION | CITRULLINATED PROTEINS | FC-GAMMA RECEPTORS | II COLLAGEN | PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTIBODY-INDUCED ARTHRITIS | TEC FAMILY KINASES | Tumor Necrosis Factor-alpha - metabolism | Arthritis, Experimental - drug therapy | Autoantibodies - metabolism | Protein-Tyrosine Kinases - therapeutic use | Arthritis, Experimental - metabolism | Arthritis, Rheumatoid - metabolism | Protein-Tyrosine Kinases - pharmacology | Protein Kinase Inhibitors - chemistry | Benzamides - therapeutic use | Arthritis, Rheumatoid - drug therapy | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Interleukin-1beta - metabolism | Myeloid Cells - immunology | Protein-Tyrosine Kinases - chemistry | Tumor Necrosis Factor-alpha - immunology | Myeloid Cells - drug effects | Benzamides - pharmacology | Phosphorylation - drug effects | Interleukin-6 - metabolism | B-Lymphocytes - metabolism | Benzamides - chemistry | Bridged Bicyclo Compounds, Heterocyclic - chemistry | Interleukin-1beta - immunology | Arthritis, Experimental - immunology | Enzyme Activation - drug effects | B-Lymphocytes - drug effects | Autoantibodies - immunology | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | B-Lymphocytes - immunology | Protein Kinase Inhibitors - therapeutic use | Interleukin-6 - immunology | Myeloid Cells - metabolism | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Arthritis, Rheumatoid - immunology | Arthritis | Biochemistry | Inhibitor drugs | Kinases | Binding sites
Journal Article
2006, Cancer drug discovery and development, ISBN 158829384X, xiii, 290
Leading researchers, from the Novartis group that pioneered Gleevec/Glivec™ and around the world, comprehensively survey the state of the art in the drug... 
Chemotherapy | Inhibitors | Protein-tyrosine kinase | Therapeutic use | Cancer | Biology, life sciences
Book
Journal of Clinical Investigation, ISSN 0021-9738, 05/2009, Volume 119, Issue 5, pp. 1109 - 1123
Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | MALIGNANT GLIOMA-CELLS | BLAST CRISIS | CLINICAL RESISTANCE | BCR-ABL MUTATIONS | ENDOPLASMIC-RETICULUM | CYTOCHROME-C RELEASE | CASPASE ACTIVATION | IMATINIB RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Transcription Factor CHOP - genetics | Neoplastic Stem Cells - cytology | Gene Expression - drug effects | Calcium - metabolism | Gene Expression - genetics | Microtubule-Associated Proteins - metabolism | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Endoplasmic Reticulum - metabolism | Antineoplastic Agents - therapeutic use | Autophagy - physiology | Thiazoles - therapeutic use | Autophagy - drug effects | Chloroquine - pharmacology | Neoplastic Stem Cells - metabolism | RNA Interference | Endoplasmic Reticulum - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Macrolides - pharmacology | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Dasatinib | Chloroquine - therapeutic use | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Mice, Inbred C3H | Xenograft Model Antitumor Assays | Fusion Proteins, bcr-abl - genetics | Animals | Cell Death - physiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Macrolides - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Causes of | Physiological aspects | Genetic aspects | Chronic myeloid leukemia | Research | Drug therapy | Phagocytosis
Journal Article
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 10/2013, Volume 188, Issue 7, pp. 770 - 775
The remarkable success of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in patients with EGFR... 
Molecular targeted therapy | Lung cancer | Cancer genomics | RET | GEFITINIB | EML4-ALK FUSION GENE | KINASE INHIBITOR | ALK INHIBITOR | SOMATIC MUTATIONS | EGFR | CHEMOTHERAPY | lung cancer | PHASE-II TRIAL | RESPIRATORY SYSTEM | CRIZOTINIB | cancer genomics | molecular targeted therapy | CRITICAL CARE MEDICINE | Lung Neoplasms - drug therapy | Oncogene Proteins - genetics | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Adenocarcinoma of Lung | Receptor, ErbB-2 - genetics | Genomics | Humans | ErbB Receptors - genetics | Antineoplastic Agents - therapeutic use | ErbB Receptors - therapeutic use | Anaplastic Lymphoma Kinase | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adenocarcinoma - genetics | ras Proteins - drug effects | Receptor, ErbB-2 - drug effects | Molecular Targeted Therapy - methods | Lung Neoplasms - genetics | Proto-Oncogene Proteins - drug effects | Carcinoma, Non-Small-Cell Lung - genetics | Proto-Oncogene Proteins c-met - drug effects | Proto-Oncogene Proteins - genetics | Mutation - genetics | Adenocarcinoma - drug therapy | Oncogene Proteins - drug effects | Proto-Oncogene Proteins c-met - genetics | Mutation - drug effects | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - drug effects | Proto-Oncogene Proteins B-raf - genetics | Receptor Protein-Tyrosine Kinases - therapeutic use | Proto-Oncogene Proteins c-ret - drug effects | Carcinoma, Non-Small-Cell Lung - drug therapy | Proto-Oncogene Proteins c-ret - genetics | Pulmonary
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 482 - 487
Journal Article